Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital
Cutaneous immune-related adverse events (cirAEs) may be associated with tumoral response and survival in patients using immune checkpoint inhibitors, but this relationship remains unclear because previous reports on the topic have various limitations. The purpose of this study was to examine the ass...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2025-01-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actadv/article/view/42023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560992397393920 |
|---|---|
| author | Gloria Juan-Carpena Natividad Martínez Banaclocha Juan Carlos Palazón Cabanes Maria Niveiro-de Jaime Isabel Betlloch Mas Mar Blanes-Martínez |
| author_facet | Gloria Juan-Carpena Natividad Martínez Banaclocha Juan Carlos Palazón Cabanes Maria Niveiro-de Jaime Isabel Betlloch Mas Mar Blanes-Martínez |
| author_sort | Gloria Juan-Carpena |
| collection | DOAJ |
| description | Cutaneous immune-related adverse events (cirAEs) may be associated with tumoral response and survival in patients using immune checkpoint inhibitors, but this relationship remains unclear because previous reports on the topic have various limitations. The purpose of this study was to examine the association of cirAEs with overall survival and progression-free survival in patients starting immune checkpoint inhibitors. A prospective observational study was conducted in a Spanish tertiary care hospital, including participants between March 2020 and May 2022. The statistical analysis involved the Kaplan–Meier method, log-rank test, and multivariable Cox proportional hazards regression models. At total of 189 patients were included, of whom 82 (43.4%) presented cirAEs. Most participants (56.6%) were diagnosed with non-small cell lung cancer (NSCLC). Mortality and progression rates were lower in patients with vs without cirAEs (p < 0.0001). Cox models showed that cirAEs were a protective factor for overall survival (adjusted HR 0.50; p < 0.0001) and progression-free survival (adjusted HR 0.54; p = 0.001) independently of cancer type, tumour stage or immune checkpoint inhibitor category. There were similar results for extracutaneous irAEs. A limitation was the single-centre design. CirAE occurrence is positively associated with longer survival and less cancer progression among immune checkpoint inhibitor recipients independently of other factors.
|
| format | Article |
| id | doaj-art-c1787dd596ef4cbaaff34fa6005b5452 |
| institution | Kabale University |
| issn | 0001-5555 1651-2057 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj-art-c1787dd596ef4cbaaff34fa6005b54522025-01-03T08:46:02ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572025-01-0110510.2340/actadv.v105.42023Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care HospitalGloria Juan-Carpena0https://orcid.org/0000-0002-4541-5328Natividad Martínez Banaclocha1Juan Carlos Palazón Cabanes 2Maria Niveiro-de Jaime3Isabel Betlloch Mas4Mar Blanes-Martínez5Department of Dermatology, Morales Meseguer University Hospital, Murcia, Spain; Toxirel Investigation GroupToxirel Investigation Group, Alicante Spain; Department of Oncology, Dr. Balmis University General Hospital, Alicante, Spain; Institute for Health and Biomedical Research (ISABIAL), Alicante, SpainDepartment of Dermatology, 12 de Octubre University Hospital, Madrid, SpainInstitute for Health and Biomedical Research (ISABIAL), Alicante, Spain; Department of Pathology, Alicante University General Hospital, Alicante, SpainInstitute for Health and Biomedical Research (ISABIAL), Alicante, Spain; Department of Dermatology, Dr. Balmis University General Hospital, Alicante, Spain; Miguel Hernández University of Elche, Alicante, SpainToxirel Investigation Group, Alicante Spain; Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain; Department of Dermatology, Dr. Balmis University General Hospital, Alicante, SpainCutaneous immune-related adverse events (cirAEs) may be associated with tumoral response and survival in patients using immune checkpoint inhibitors, but this relationship remains unclear because previous reports on the topic have various limitations. The purpose of this study was to examine the association of cirAEs with overall survival and progression-free survival in patients starting immune checkpoint inhibitors. A prospective observational study was conducted in a Spanish tertiary care hospital, including participants between March 2020 and May 2022. The statistical analysis involved the Kaplan–Meier method, log-rank test, and multivariable Cox proportional hazards regression models. At total of 189 patients were included, of whom 82 (43.4%) presented cirAEs. Most participants (56.6%) were diagnosed with non-small cell lung cancer (NSCLC). Mortality and progression rates were lower in patients with vs without cirAEs (p < 0.0001). Cox models showed that cirAEs were a protective factor for overall survival (adjusted HR 0.50; p < 0.0001) and progression-free survival (adjusted HR 0.54; p = 0.001) independently of cancer type, tumour stage or immune checkpoint inhibitor category. There were similar results for extracutaneous irAEs. A limitation was the single-centre design. CirAE occurrence is positively associated with longer survival and less cancer progression among immune checkpoint inhibitor recipients independently of other factors. https://medicaljournalssweden.se/actadv/article/view/42023overall survival (OS)progression-free survivalcutaneous immune-related adverse eventsImmune Checkpoint Inhibitorsskin toxicityimmunotherapy |
| spellingShingle | Gloria Juan-Carpena Natividad Martínez Banaclocha Juan Carlos Palazón Cabanes Maria Niveiro-de Jaime Isabel Betlloch Mas Mar Blanes-Martínez Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital Acta Dermato-Venereologica overall survival (OS) progression-free survival cutaneous immune-related adverse events Immune Checkpoint Inhibitors skin toxicity immunotherapy |
| title | Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital |
| title_full | Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital |
| title_fullStr | Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital |
| title_full_unstemmed | Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital |
| title_short | Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital |
| title_sort | association of cutaneous immune related adverse events with overall survival and progression free survival in oncology patients receiving immune checkpoint inhibitors a prospective study of 189 patients in a spanish tertiary care hospital |
| topic | overall survival (OS) progression-free survival cutaneous immune-related adverse events Immune Checkpoint Inhibitors skin toxicity immunotherapy |
| url | https://medicaljournalssweden.se/actadv/article/view/42023 |
| work_keys_str_mv | AT gloriajuancarpena associationofcutaneousimmunerelatedadverseeventswithoverallsurvivalandprogressionfreesurvivalinoncologypatientsreceivingimmunecheckpointinhibitorsaprospectivestudyof189patientsinaspanishtertiarycarehospital AT natividadmartinezbanaclocha associationofcutaneousimmunerelatedadverseeventswithoverallsurvivalandprogressionfreesurvivalinoncologypatientsreceivingimmunecheckpointinhibitorsaprospectivestudyof189patientsinaspanishtertiarycarehospital AT juancarlospalazoncabanes associationofcutaneousimmunerelatedadverseeventswithoverallsurvivalandprogressionfreesurvivalinoncologypatientsreceivingimmunecheckpointinhibitorsaprospectivestudyof189patientsinaspanishtertiarycarehospital AT marianiveirodejaime associationofcutaneousimmunerelatedadverseeventswithoverallsurvivalandprogressionfreesurvivalinoncologypatientsreceivingimmunecheckpointinhibitorsaprospectivestudyof189patientsinaspanishtertiarycarehospital AT isabelbetllochmas associationofcutaneousimmunerelatedadverseeventswithoverallsurvivalandprogressionfreesurvivalinoncologypatientsreceivingimmunecheckpointinhibitorsaprospectivestudyof189patientsinaspanishtertiarycarehospital AT marblanesmartinez associationofcutaneousimmunerelatedadverseeventswithoverallsurvivalandprogressionfreesurvivalinoncologypatientsreceivingimmunecheckpointinhibitorsaprospectivestudyof189patientsinaspanishtertiarycarehospital |